Publication of Chikungunya Vaccine Candidate, VLA 1553, phase III data in The Lancet
Valneva SE announces that the Company’s pivotal Phase III data for its single-shot chikungunya vaccine candidate, VLA 1553, have been published in The Lancet, the world’s leading peer-reviewed medical journal
The article, titled “Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicenter, randomized, placebo-controlled phase III trial” provides a detailed analysis of the Phase III results showing that VLA 1553 demonstrated a very high sero-response rate of 98.9% in participants 28 days after receiving the single administration. This immunogenicity profile was similar in both younger and older adults, and 96% of participants maintained sero-response six months after vaccination. VLA 1553 was generally safe and equally well tolerated in younger and older adults. The Lancet Paper can be accessed via the following link: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00641-4/fulltext.
Valneva reported final pivotal Phase III data in March 2022, final lot-to-lot consistency results in May 2022 and positive twelve-month persistence data in December 2022. A clinical study of VLA 1553 in adolescents is ongoing in Brazil, for which Valneva reported enrollment and vaccination completion in February 2023.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.